Switching from brand-name to generic psychotropic medications: a literature review.
about
A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic)Potential Clinical and Economic Impact of Switching Branded Medications to Generics.Rational use of generic psychotropic drugs.Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study.Pharmacy switch of antipsychotic medications: patient's perspective.Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.The introduction of generic risperidone in Medicare Part DDrug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.Generic formulations of psychotropic medications and treatment responseIdentification of non-reported bupropion metabolites in human plasma.Impact of brand-name drug worship and expectation psychology on antidepressant efficacyMixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.Advancing pharmaceuticals and patient safety in Saudi Arabia: A 2030 vision initiative.Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.
P2860
Q26779556-4512E152-6896-42E7-B25E-66A33136890EQ33637817-4AD9769F-354C-47DA-9B43-09061F3E7986Q34688387-018D9AF7-05C8-446A-8ED2-E40379F5390DQ35008178-26E4C280-2211-472B-86BB-8B9762EB29B6Q35859096-300AE24F-7917-4D3C-A7BA-E8AAFBC4D708Q36093400-C66FDD3F-FA3A-4A57-8714-9743878AD15EQ36512458-2F128B31-212C-4101-9BC8-E536748CA69BQ36916999-156D3454-DA1C-4232-A027-D1259EF2480DQ37024443-D95CA6EB-3058-41F2-85F5-927171D92A78Q37574860-AA95F6B2-7FE0-4986-847B-5600771CE60FQ38532357-CFCFCA58-5C2E-43A9-9E16-1FAAB3E95621Q40706829-B9124526-ACA6-4561-8B07-302C88BBAF99Q42293277-9CD5B3F2-9710-4A92-A7A9-AB291CF34830Q42360559-3E27088A-51C8-4EE3-93D0-AFCD016A0BD3Q42584470-AE8C6F27-A419-42BE-83AC-110EEF0F8443Q47381084-DBEACBF4-EF2C-4A3E-AF02-891F07609FFFQ49260603-AD87AA0D-F46A-481E-B1F9-719D189E8AD0Q50617008-BE175155-803E-4564-910F-522262D36207Q51202982-1B37B243-600F-4F90-BADD-28F1EC668B77
P2860
Switching from brand-name to generic psychotropic medications: a literature review.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Switching from brand-name to generic psychotropic medications: a literature review.
@en
Switching from brand-name to generic psychotropic medications: a literature review.
@nl
type
label
Switching from brand-name to generic psychotropic medications: a literature review.
@en
Switching from brand-name to generic psychotropic medications: a literature review.
@nl
prefLabel
Switching from brand-name to generic psychotropic medications: a literature review.
@en
Switching from brand-name to generic psychotropic medications: a literature review.
@nl
P2093
P2860
P31
P1476
Switching from brand-name to generic psychotropic medications: a literature review
@en
P2093
Howard C Margolese
Julie Eve Desmarais
Linda Beauclair
P2860
P304
P356
10.1111/J.1755-5949.2010.00210.X
P577
2010-11-30T00:00:00Z